| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.21 | 0.2 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.037 | 0.2 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.2 |